Articles tagged with Drug Discovery
A new technology dubbed MorphEUS enables rapid screening of drug candidates against Mycobcterium tuberculosis (M. tb), the bacterium that causes TB. It uses high throughput imaging and machine learning to uncover patterns in how antibacterials kill, improving the efficiency and effectiveness of treatment development.
A study supported by the Alzheimer's Drug Discovery Foundation found that rotigotine, a dopamine-acting drug, improved frontal lobe executive function and daily activities in patients with mild-to-moderate Alzheimer's disease. The treatment also enhanced dopaminergic pathways reaching this section of the brain.
Researchers at Istituto Italiano di Tecnologia have discovered a novel chemical compound that shows promise in treating core symptoms of brain disorders such as Down syndrome and autism. The new compound selectively blocks the transporter NKCC1, which is dysregulated in these conditions.
Eugenia Trushina, Ph.D., Mayo Clinic Rochester researcher, receives $600,000 to develop new drug candidates restoring mitochondrial function in treating Alzheimer's. The ADDF-Harrington partnership aims to accelerate discovery into clinical studies for a potential cure.
TARA's in vitro human cardiac models replicate drug responses similar to those observed in humans, supporting their use as a robust platform for new medicines evaluation. The models' ability to reproduce diverse mechanisms of action showcases their applicability for cardiac drug discovery and development.
Researchers developed a machine learning algorithm to predict six major clinical forms of drug-induced cardiac toxicity from gene expression data. The model demonstrated generalizability and was validated on an independent dataset, with potential applications in enhancing pharmaceutical industry safety evaluation.
Scientists have discovered a new killing mechanism in teixobactin, a potent natural antibiotic that can kill superbugs. The research provides fundamental insights into how teixobactins work and could lead to the development of new drugs.
KinaRx LLC, a Purdue University-affiliated startup, has received a $2 million SBIR grant to develop novel kinase inhibitors for treating relapse in acute myeloid leukemia (AML) and other diseases. The company's platform aims to rapidly create complex drug molecules using bioinformatics and multi-component compound synthesis.
Research at Kobe University reveals that metformin causes blood sugar to be excreted in the stool, promoting its removal from the intestine. This discovery contributes to understanding the mechanism of metformin's biological effects and may lead to the development of new drugs for diabetes.
A special collection in SLAS Discovery highlights new screening tools and assays for ion channel drug discovery. The articles cover various techniques such as optical and automated patch clamp electrophysiology to identify new chemical matter for medically relevant membrane protein targets.
The Chemical Checker tool uses a similarity principle to analyze over 1M compounds and identify potential treatments for diseases. It has been used to reposition approved drugs for Alzheimer's disease and identify substitutes for expensive biologics.
A team of computational scientists, medicinal chemists, biochemists, and virologists have coalesced to rapidly identify drug-like molecules that inhibit SARS-CoV-19 replication. They are leveraging powerful supercomputers to screen millions of small molecules against all the major non-structural proteins of SARS-CoV-19.
Researchers are developing new metal catalysts for drug discovery, potentially offering lower therapeutic dosages and fewer side effects. The project aims to create synthetic forms of biological macromolecules that detoxify aldehydes, addressing biochemical imbalance and disease development.
Researchers unveil the structure of a key protein in human metabolism, which could lead to better obesity treatments. The study found that calcium ions play a crucial role in the protein's function, opening new paths for developing targeted pharmaceuticals.
A USC-led team of scientists has discovered the precise shape of the melanocortin 4 receptor, a key player in human metabolism. The findings could lead to more effective therapies for obesity and other metabolic diseases, which affect millions worldwide.
Multispecific drugs have the potential to target 85% of currently thought-of-as-undruggable proteins. By inducing proximity between targets and natural enzymes or cells, they can harness biology's power to go beyond conventional drugs.
An international team of researchers has identified six potential COVID-19 treatment candidates after testing over 10,000 compounds. The targeted therapeutics were found to be effective in inhibiting the main protease enzyme of the virus.
Gero's AI platform identifies 9 potential COVID-19 treatments among existing drugs, including Niclosamide and Nitazoxanide. The list enables urgent clinical trials to begin in weeks.
Experts debate nationalizing the pharmaceutical sector to improve public health priorities, address extortionate pricing, and ensure patient access to new advanced drugs. Mariana Mazzucato and Henry Lishi Li propose a government-provided quality-assured medicine option that co-exists with private sector products.
The discovery of CRISPR-Cas9 systems has revolutionized pharmaceutical research by allowing for industrial-scale gene editing and functional genomic screening. This enables the identification of new biological targets for precision medicines and the exploration of mechanisms of drug resistance and sensitivity ahead of clinical trials.
A novel injectable drug, NOV004, is being developed by Novosteo Inc. to heal broken bones faster and strengthen weak bones. The treatment concentrates at the fracture site while reducing exposure to the rest of the body, potentially reducing mortality rates among older adults.
Researchers at Emory University have developed a new approach to organic synthesis that can efficiently transform simple molecules into complex ones with 3D structures. This method opens up whole new chemical space for potential drug targets, enabling the creation of more direct and efficient pathways for pharmaceutical research.
A new minimally invasive treatment has shown significant improvement in symptoms and quality of life for patients with thyroid eye disease. The drug, teprotumumab, blocks inflammatory autoimmune pathophysiology and has the potential to alter the course of the disease.
Calibr's novel cell therapy leverages a patient's own immune cells, directing them to engage cancer targets with a control switch. Clinical trials will test the approach in patients with relapsed/refractory B-cell malignancies.
Researchers are developing long-acting formulations for malaria and TB prevention, as well as a single-injection cure for hepatitis C. The project aims to improve patient adherence and reduce disease transmission in low- and middle-income countries.
Researchers mapped protein-drug interactions in rat organs and blood, revealing potential drug targets. The study represents a significant advancement for translational research, allowing direct monitoring of biological changes in an organ.
Researchers at the University of Dundee are working on a new effort to tackle tuberculosis, identifying new treatment options for the disease. With a $3 million grant from the Bill & Melinda Gates Foundation, they aim to improve drug discovery and develop new candidate drugs to treat TB.
Lemon, a new framework, enables faster extraction of biological information from large datasets, enhancing drug development. The software can process PDB data in minutes, reducing time from hours to seconds.
The National Cancer Institute's Plated Compound Sets provide a convenient and cost-effective way to screen compounds manually. However, some collections contain pan assay interfering and nonspecific compounds that can generate false hits.
Researchers developed a free online app, eNTRyway, to speed up the discovery of new antibiotics for Gram-negative bacteria. The tool quickly evaluates potential drug compounds and can convert existing drugs into potent killers of Gram-negative pathogens.
TARA Biosystems' human heart-on-a-chip technology shows promise in predicting preclinical systolic and diastolic in vivo observations for novel cardiac drug MYK-491. The platform uses human induced pluripotent stem cells to create physiologically relevant cardiac tissues.
Researchers have identified a new enzyme that inhibits the LRRK2 pathway, which is responsible for most genetic cases of Parkinson's disease. The discovery provides hope for developing new treatments and suggests that the enzyme could benefit all individuals, regardless of whether they have Parkinson's or not.
Researchers at the University of Dundee have discovered an enzyme that could prevent Group A Streptococcus infections by inhibiting a carbohydrate coating on the bacterium's surface. The discovery offers new opportunities for developing antimicrobial drugs with minimal off-target effects.
Chemists at Ohio State University have discovered a new way to synthesize the most common molecule arrangement in medicine, which could make it easier and more efficient for drug makers to produce medicines. This breakthrough could lead to a reduction in waste and an improvement in the production process.
A new drug discovery platform created by Purdue University scientists has the potential to predict the effectiveness of psychoactive drugs in treating mental health illnesses. The platform analyzes compound interactions with proteins and identifies signature patterns for potential therapeutic uses.
The company has proposed a new family of prior distributions: TRIP, which improves Fréchet Inception Distance for GANs and Evidence Lower Bound for VAEs. The model was experimentally validated in cells and animals, demonstrating its potential for accelerating drug discovery.
George Mason University researchers have discovered the exact location where two proteins responsible for hiding cancer cells from the immune system bind. The protein painting technology enables rapid performance testing of drugs, producing results in several days instead of years.
The IU-led center will focus on proteins related to the brain's immune system that may contribute to Alzheimer's disease. The goal is to develop high-quality research tools and new technologies needed to broaden the number of targets being investigated for effective medicines.
Researchers are using cloning to recreate esophageal cancer development, identifying potential targets for therapies before the disease becomes fatal. The goal is to develop effective drugs in a fraction of the time it takes Big Pharma.
The National Institute on Aging has awarded a grant to establish the Open-AD Drug Discovery Center, which aims to accelerate the development of new drugs for Alzheimer's disease. The center will develop research platforms and openly distribute tools to test the efficacy of Alzheimer's therapies.
Researchers developed a method to categorize drugs based on cellular responses, predicting potential clinical effects and reducing side effects. The approach was validated using opioid analgesics, with potential applications in safer opioids and cannabis product testing.
Researchers have developed an AI-powered drug discovery tool that validates novel drug candidates in just 46 days, significantly reducing the traditional 2-3 year timeline. The foundation aims to motivate researchers to harness AI's potential in longevity research and encourage larger developers to adopt AI-powered programs.
Researchers develop algorithm that can predict complex chemical reactions and provide a 'chemical map' to desired products, reducing time in preclinical drug discovery and materials science. The model achieves high accuracy by distilling patterns of reactivity from millions of published chemical reactions.
A recent study demonstrates the use of Generative Tensorial Reinforcement Learning (GENTRL) to design and validate a novel drug candidate against fibrosis and cancer. The AI process accelerated the development from 46 days, reducing the time estimate by approximately 94%.
A new AI system, Generative Tensorial Reinforcement Learning (GENTRL), was used to generate six novel inhibitors of DDR1 kinase target in just 21 days. Four compounds showed activity in biochemical assays, and one lead candidate demonstrated favorable pharmacokinetics in mice.
Patrick M. Woster, Ph.D., has been inducted into the Medicinal Chemistry Hall of Fame for his significant contributions to the field, including the discovery of novel therapeutics such as antimalarial and antibacterial agents. His work also emphasizes the crucial role of medicinal chemists in the drug discovery pipeline.
Quantifying physicochemical properties is crucial for understanding drug interactions and mechanisms. The article highlights the importance of using contemporary methods to improve subpar testing outcomes, enabling better structure-property relationships and accelerated predictive models.
Northwestern University scientists have received a $3.1 million grant to investigate drug therapies for ALS, targeting protein aggregation and upper motor neurons. Promising early results suggest compounds may have broader applications for neurodegeneration.
The study demonstrated the potential of body-on-a-chip systems to transform the drug discovery process by accurately predicting cardiotoxic mechanisms and replicating in vivo results. The findings support the use of in vitro models to evaluate temporal pharmacokinetic/pharmacodynamic relationships.
Researchers at Harvard University have synthesized sufficient quantities of the potent anti-cancer agent E7130 to enable rigorous studies of its biological activity, pharmacological properties, and efficacy. The team's achievement is a landmark in drug discovery, providing new insights into the molecule's complex mode of action and pot...
Researchers at Dartmouth College developed a new strategy for drug discovery and development, enabling the creation of targeted therapies against cancer and neurodegeneration. The technique produces potent compounds selectively toxic to glioblastoma while showing minimal harm to healthy brain cells.
The June issue of SLAS Technology introduces a new sample management collection, enabling the use of disease-relevant cells and tissues in miniaturized biology. This shift reduces drug discovery attrition by mimicking the disease state more effectively.
A leading scientist proposes five rules to tackle antibiotic resistance, including protecting new drugs and using diverse antimicrobials. The World Health Organisation warns of a post-antibiotic era, and the study aims to provide a roadmap for integrated microbial management.
Researchers have developed a method to identify potential targets for new drugs using live blood cells from patients with mental health disorders. The approach has the potential to accelerate drug discovery and personalized medicine for neuropsychiatric disorders, reducing animal testing and improving treatment outcomes.
A new digital filter approach aims to improve chemical measurements, enabling faster drug development and clinical trials. The technology, developed by Purdue University professor Garth Simpson, uses non-negative matrix factorization to analyze large data sets and remove timing artifacts.
Researchers at Tel Aviv University have discovered a homeostatic mechanism that regulates brain activity in neural circuits, paving the way for new treatments of epilepsy. A commonly used medication for multiple sclerosis may also be effective in suppressing seizures in patients with Dravet syndrome.
Researchers from Hong Kong Baptist University have invented a new method that can detect target molecules in pharmaceuticals and pesticides in just five minutes. This breakthrough could lead to the production of higher quality medicinal drugs with no side effects.
Researchers have developed a new chemical synthesis strategy, pharmacophore-directed retrosynthesis (PDR), to harvest information from natural products and identify novel, simpler derivatives. This approach may lead to selective protection of neurons and prevention of immune system rejection in organ transplants.
A new project at the Carl R. Woese Institute for Genomic Biology aims to discover a thousand new ribosomally synthesized and post-translationally modified peptides (RiPPs) using synthetic biology and automation. The project uses an automated robotic system, called iBioFAB, to identify new RiPPs and create new molecules.
DNDi and Atomwise collaborate to develop first-in-class treatments for Chagas disease using AI, delivering drug-like compounds that will undergo further optimization and potential drug development. The research aims to address a public health challenge affecting millions worldwide.